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PURPOSE. To compare the efficacy of behavioral activation (BA) plus low vision rehabilitation
with an occupational therapist (OT-LVR) with supportive therapy (ST) on visual function in
patients with age-related macular degeneration (AMD).
METHODS. Single-masked, attention-controlled, randomized clinical trial with AMD patients
with subsyndromal depressive symptoms (n ¼ 188). All subjects had two outpatient low
vision rehabilitation optometry visits, then were randomized to in-home BA þ OT-LVR or ST.
Behavioral activation is a structured behavioral treatment aiming to increase adaptive
behaviors and achieve valued goals. Supportive therapy is a nondirective, psychological
treatment that provides emotional support and controls for attention. Functional vision was
assessed with the activity inventory (AI) in which participants rate the difficulty level of goals
and corresponding tasks. Participants were assessed at baseline and 4 months.
RESULTS. Improvements in functional vision measures were seen in both the BA þ OT-LVR and
ST groups at the goal level (d ¼ 0.71; d ¼ 0.56 respectively). At the task level, BA þ OT-LVR
patients showed more improvement in reading, inside-the-home tasks and outside-the-home
tasks, when compared to ST patients. The greatest effects were seen in the BA þ OT-LVR
group in subjects with a visual acuity ‡20/70 (d ¼ 0.360 reading; d ¼ 0.500 inside the home;
d ¼ 0.468 outside the home).
CONCLUSIONS. Based on the trends of the AI data, we suggest that BA þ OT-LVR services,
provided by an OT in the patient’s home following conventional low vision optometry
services, are more effective than conventional optometric low vision services alone for those
with mild visual impairment. (ClinicalTrials.gov number, NCT00769015.)
Keywords: visual function, depression, age-related macular degeneration, low vision
rehabilitation
Age-related macular degeneration (AMD) is a degenerativeeye disease that leads to progressive central vision loss,
which can severely affect an individual’s ability to socialize,
read, drive, and live independently.1–4 An estimated 10% to 30%
of visually impaired patients with AMD develop clinically
significant depression.5–6 Depression in AMD is associated with
a decline in visual function and greater levels of disability,
medical costs, and mortality rates.7–11 Clinical research studies
demonstrate that outpatient low vision rehabilitation services
can improve functional ability.12–19 A recently completed
clinical trial, the Low Vision Depression Prevention Trial in
Age-Related Macular Degeneration (VITAL), demonstrated that
behavioral activation (BA) plus low vision rehabilitation
delivered by an occupational therapist (OT-LVR) in the patients’
home reduced the incidence of severe depression in high-risk
AMD patients with low vision.20
Participants in both the active treatment and control groups
(a placebo condition to control for attention) in the VITAL
study received conventional low vision evaluation and low
vision optometry services provided in an outpatient optometric
clinic prior to randomization. Only the active treatment group
was given BA þ OT-LVR. The supportive therapy (ST) control
group received an equal amount of in-home attention from a
social worker or counselor, but did not receive any additional
low vision rehabilitation services or advice. Because patients’
functional ability was measured in the VITAL study by
administering the activity inventory (AI), an adaptive self-report
rating scale instrument, before the initial low vision evaluation
by the optometrist and again 4 months later after their
respective in-home interventions (masked to treatment assign-
ment), we have the opportunity to evaluate the effectiveness of
adding in-home BA þ LVR to optometric low vision services,
with a control for the potential response-biasing effects on
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functional outcome measures of attention from an empathetic
and supportive therapist.
The purpose of the present study is to evaluate the
functional outcomes of visually impaired AMD patients using
secondary functional outcome measures from the VITAL study.
We are interested in learning if in-home BAþ LVR provided by
an occupational therapist added to conventional optometric
low vision services are more effective in improving the
patients’ functional ability than are conventional optometric
low vision services plus in-home supportive therapy provided
as an attention control.
METHODS
Subjects
Eligibility criteria were: (1) age >65 years; (2) bilateral AMD
(either neovascular disease or geographic atrophy); (3) best
eye corrected visual acuity <20/70; (4) >5 anti-VEGF
injections if the better eye had neovascular disease (or no
injections in past 3 months); (5) moderate difficulty perform-
ing a valued activity; and (6) subthreshold depressive
symptoms, defined as a Patient Health Questionnaire-9 (PHQ-
9) score of >521 or depressed mood or anhedonia several days
per week. We excluded patients with cognitive deficits
(assessed by an abbreviated version of the Mini Mental State
Exam),22 impending anti-VEGF treatment, diagnosis of major
depression, dysthymia, or other axis I psychiatric disorder as
defined by Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV), or other ophthalmologic
disease.
Medical charts were reviewed to identify those who met
eligibility criteria. Recruitment letters were mailed and
followed by telephone calls by a research assistant to ascertain
study interest and to screen for eligibility (depressive
symptoms, cognitive functioning, and difficulty with valued
activities). A research nurse then visited participants in their
homes to obtain informed consent and to administer the
baseline assessment. All procedures were approved by the
Institutional Review Board at Thomas Jefferson University and
adhered to the tenets of the Declaration of Helsinki.
Procedures
After the baseline assessment, all subjects had two visits with a
study optometrist before randomization into the two treatment
groups. The optometrists provided their usual low vision
evaluation and patient training in the clinic. Up to $350 was
provided to each subject toward the purchase of low vision
devices as recommended by the low vision optometrist.
Subjects were randomized using a random numbers table
and fixed scheme with a 1:1 allocation ratio. Assignment to
each treatment group was stratified by severity of vision loss.
The BAþOT-LVR treatment arm received services by an OT to
address depression and functional limitations from vision loss.
This intervention involved six in-home 1-hour sessions over a
period of 8 weeks with one of five study OTs. The behavioral
activation component of the intervention emphasized links
between action, mood, and mastery and promoted self-efficacy
and social connection. The low vision rehabilitation compo-
nent of the intervention followed an occupational therapy plan
of care based on the evaluation results and patient goals. The
occupational therapists had regular communication with the
treating optometrists to update them on subjects’ progress
with their goals. The supportive therapy group received
services from social workers or counselors who provided
emotional support. These services involved six in-home 1-hour
sessions with one of three study social workers/counselors
over a period of 8 weeks. Supportive therapy, which
emphasized personal expression about vision loss and disabil-
ity, was designed to control for nonspecific effects of attention.
Aside from the initial LVR services received from the
optometrist, no additional in-home LVR services were provided
to the subjects in the ST group.
Relevant to the present study, self-reported functional
ability was measured using the AI at baseline and 4 months
after treatment.23–26 Also included were measures of depres-
sion using the PHQ-9.21,27,28 Vision impairment measures
consisted of distance and near visual acuity (VA), contrast
sensitivity, and size and locations of central scotomas. The
primary outcome measure in the trial was diagnosis of
depression as defined in the VITAL study report.20 Here we
analyze the functional outcome measures for the two
treatment groups from patient responses to the AI.
Measures
The activity inventory and PHQ-9 were administered by a nurse
in the patient’s home at baseline prior to the optometrist’s low
vision evaluation and services and again 4 months later (65
days) after completion of BA þ OT-LVR or ST provided in the
home. The activity inventory consists of 50 goal-level activities
(e.g., manage personal finances, prepare daily meals) and an
item bank of 460 tasks (e.g., specific cognitive and motor
activities such as read bills, write checks, measure ingredients,
and pour liquids), nested under the 50 goals. The subject was
asked to rate the importance of performing each goal activity
without depending on another person (not important, slightly
important, moderately important, very important). If the goal
was rated not important, the interviewer moved on to the next
goal. If the goal was rated at least slightly important, the
interviewer asked the subject to rate the difficulty of
performing the goal activity without depending on another
person (not difficult, slightly difficult, moderately difficult, very
difficult, or impossible). If the goal was rated not difficult, the
interviewer moved on to the next goal. If the goal was rated at
least slightly difficult, the subject was asked to rate the
difficulty of the tasks nested under that goal (using the same
rating categories used for the goal, or the subject could
respond that the task is not applicable to the way they perform
the goal activity).23
The research nurse then verified depression eligibility by
administering the PHQ-9, a self-report questionnaire designed
to provide information on specific disorders using the criteria
from the DSM, at the baseline assessment. Rasch analysis of the
patients’ responses to the PHQ-9 was used in the present study
to estimate a continuous interval-scaled ‘‘depression severity’’
variable.27,28
Analyses
Rasch analysis, employing the Andrich rating scale model,29,30
was used to estimate four different visual ability measures, one
from subjects’ difficulty ratings of AI goals and three from
subjects’ difficulty ratings of subsets of AI tasks (reading, inside-
the-home and outside-the-home tasks). Previous studies have
shown that two independent visual function factors underlie
visual ability measures estimated from difficulty ratings of
activities, one related to visual acuity and the other related to
loss of peripheral vision and/or scotomas.31 Visual ability
estimated from goal difficulty ratings fall close to the principal
axis in the two-factor space (i.e., loading approximately equally
on the two factors). Person measures estimated from different
combinations of tasks fall in the same two-factor space, but
plot at different positions depending on the ratio of overall
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dependence on the acuity-related factor to overall dependence
on the scotoma-related factor of the sample of tasks. Because
rehabilitation is expected to increase functional reserve (i.e.,
difference between the person’s visual ability [person mea-
sure] and the visual ability required to perform the activity
described by the item [item measure]), AI item measures and
response category thresholds were anchored to baseline values
estimated previously from the responses of 3200 low vision
patients.32 Anchoring item measures and response category
thresholds forces all changes in functional reserve, whether
increases in the person’s ability (e.g., from refractive error
correction) or person-specific decreases in the required ability
for an item (e.g., from the use of a low vision aid), to manifest
as changes in the estimated person measures.33–34 Items that
were rated as ‘‘not difficult’’ at baseline were filtered out for
both baseline and follow-up person measure estimates, since
there is no room for improvement and they would not be
included as rehabilitation goals in the patient’s plan of care.15
We report 1-tail t-tests comparing within group differences pre-
and posttreatment and between group differences, BA þ OT-
LVR versus ST. One-tail t-test results are reported because we
are interested in whether or not patients improved in visual
function and not reporting statistics from those who report
getting worse from progression of AMD.
A minimum clinically important difference (MCID) for each
of the four visual ability measures was estimated for each
subject by subtracting the baseline person measure from the 4-
month follow-up person measure and dividing by 1.96 times
the corresponding standard error of the baseline person
measure.15 The minimum clinically important difference is
considered a clinical endpoint, so if MCID >1 for a subject (i.e.,
P < 0.05), then the effect of intervention on the measure for
that subject is given a score of 1, otherwise it is scored as 0.
Rasch analysis also was performed on the PHQ-9 responses to
estimate continuous interval–scaled measures of a depression-
related psychologic state variable (‘‘depression severity’’).27,28
One-tailed t-tests were used to compare the depression severity
distribution of patients exhibiting a significant MCID to the
distribution of patients who did not have a significant MCID.
RESULTS
Complete demographics and clinical characteristics of the 188
participating patients (BAþOT-LVR group: n¼ 96; ST group: n
¼ 92) are described in the VITAL study report.20 To summarize,
mean patient age was 84 years (range, 67–97 years) and 70.2%
were women. Best-corrected binocular visual acuity ranged
from 0.01 to 2.2 logMAR (20/20–20/3170) with a median of
0.64 logMAR (20/87). Nineteen subjects (10.1%) dropped out
of the study (BA þ OT-LVR group: 7; ST group: 12), seven
additional subjects did not complete the AI. These 26 subjects
did not differ in their distribution of PHQ-9 scores.
Tasks were categorized as either reading, inside-the-home,
or outside-the-home activities. As summarized in Table 1 with
Cohen’s d, moderate improvements in functional ability were
seen in both the BAþOT-LVR and ST groups at the AI goal level
(d¼ 0.713 and d¼ 0.559, respectively). At the AI task level, BA
þ OT-LVR patients exhibited more improvement in reading,
inside-the-home, and outside-the-home activities than did ST
patients. When comparing the functional ability outcomes and
group effects of BAþOT-LVR to ST, small differences were seen
with the functional ability measure based on ratings of inside-
the-home and outside-the-home tasks reaching statistical
significance.
Median logMAR acuity was 0.51 (~20/70). Participants
were divided into two visual acuity groups around the median
(‡20/70 and <20/70) to evaluate visual acuity effects on
functional ability outcomes. As summarized in Table 2,
significant visual acuity effects were seen in both the BA þ
OT-LVR and ST groups at the AI goal level. The greatest change
in visual ability from baseline to follow-up was seen in the BAþ
OT-LVR group subjects with VA ‡20/70 (d¼0.571, P < 0.001).
This group also exhibited the greatest improvement in
functional ability in each of the AI task categories (d ¼
0.360–0.500). Those BA þOT-LVR subjects with a VA <20/70
exhibited only small effects (d¼ 0.046–0.311). There were no
significant improvements in functional ability estimated from
task ratings for the ST group for either visual acuity category.
Moderate effects were seen at the goal and task levels when
comparing BA þ OT-LVR to ST for those patients with a VA
‡20/70. However, none of these effects reached statistical
significance after correction for multiple tests. There were
small to no group effects of BA þOT-LVR compared to ST for
subjects <20/70.
The study VITAL concluded that 11 BA þ OT-LVR subjects
(12.6%) and 18 ST subjects (23.4%) developed a depressive
disorder by the 4-month follow-up (RR, 0.54; P¼ 0.036).20 The
Figure compares changes in depression severity from baseline
to 4-month follow-up as change score histograms for the BAþ
OT-LVR group (black bars) and the ST group (gray bars).
Overall, there is no significant difference between the
depression severity change score distributions for the BA þ
OT-LVR and ST groups (P¼ 0.402). The mean change score is
1.06 (SD¼ 1.15) for the BAþOT-LVR group and0.88 (SD¼
1.45) for the ST group, which indicate reductions in
depression severity. However, if we compare the frequency
of depression severity increasing (i.e., worse depressed state)
at the 4-month follow-up (positive change scores in the
highlighted area of the Fig.), 12% of the BA þ OT-LVR group
TABLE 1. Activity Inventory Effect Size (Cohen’s d) Categorized at the Goal and Task Levels
Effect Size at 4 Months
Treatment Group Goal Reading Inside-the-Home Outside-the-Home
BA þ OT-LVR* 0.713 (P < 0.001) 0.328 (P ¼ 0.002) 0.634 (P < 0.001) 0.555 (P < 0.001)
ST† 0.559 (P < 0.001) 0.168 (P ¼ 0.14) 0.312 (P ¼ 0.012) 0.19 (P ¼ 0.15)
Group Effect‡ 0.10 (P ¼ 0.20) 0.17 (P ¼ 0.073) 0.21 (P ¼ 0.030) 0.27 (P ¼ 0.013)
* Within group comparison of BAþOT-LVR change scores (4-month follow-up person measure minus baseline person measure); The values of P
are for 1-tailed paired t-tests comparing baseline person measures to 4-month follow-up person measures estimated from difficulty ratings of AI goals
and the three sets of AI tasks (reading, inside-the-home, and outside-the-home tasks).
† Within group comparison of ST change scores (4-month follow-up person measure minus baseline person measure); The values of P are for
1-tailed paired t-tests comparing baseline person measures to 4-month follow-up person measures estimated from difficulty ratings of AI goals and
the three sets of AI tasks (reading, inside-the-home, and outside-the-home tasks).
‡ Between group comparison of change scores (4-month follow-up person measure minus baseline person measure); The values of P are for
1-tailed unpaired t-tests comparing BA þOT-LVR change scores to ST change scores.
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had an increase in depressive state at 4 months compared to
26% of the ST (P ¼ 0.015).
For the two treatment groups combined, 108 patients had
no significant improvement in visual ability estimated from
goal difficulty ratings (assigned a MCID score of 0) and 54
patients had a significant improvement (assigned a MCID score
of 1). Those subjects who had an MCID score of 1 at the goal
level had a mean depression severity change score of 1.26
while those who had a MCID score of 0 had a mean depression
severity change score of0.87 (Table 3). These results indicate
TABLE 2. Effect Size (Cohen’s d) Stratified by Visual Impairment Categorized at the Goal and Task Levels
Outcomes Stratified by Visual Impairment
Treatment/Visual Impairment Group Goal Reading Inside-the-Home Outside-the-Home
BA þ OT-LVR VA 20/70 or better* 0.571 (P < 0.001)† 0.360 (P < 0.001)† 0.500 (P < 0.001)† 0.468 (P < 0.001)†
BA þ OT-LVR VA worse than 20/70‡ 0.313 (P < 0.001)† 0.046 (P ¼ 0.30) 0.263 (P ¼ 0.003)† 0.311 (P ¼ 0.001)†
ST VA 20/70 or better§ 0.340 (P ¼ 0.0013)† 0.072 (P ¼ 0.26) 0.255 (P ¼ 0.023) 0.113 (P ¼ 0.21)
ST VA worse than 20/70jj 0.386 (P < 0.001)† 0.083 (P ¼ 0.18) 0.125 (P ¼ 0.13) 0.099 (P ¼ 0.25)
Between treatment group effect VA better than 20/70¶ 0.382 (P ¼ 0.01) 0.404 (P ¼ 0.009) 0.321 (P ¼ 0.027) 0.459 (P ¼ 0.007)
Between treatment group effect VA worse than 20/70# 0.159 (P ¼ 0.15) 0.045 (P ¼ 0.39) 0.139 (P ¼ 0.18) 0.170 (P ¼ 0.15)
Within group acuity effects BA þ OT LVR** 0.460 (P ¼ 0.002)† 0.310 (P ¼ 0.026) 0.332 (P ¼ 0.016) 0.212 (P ¼ 0.11)
Within group acuity effects ST†† 0.095 (P ¼ 0.28) 0.062 (P ¼ 0.36) 0.119 (P ¼ 0.24) 0.013 (P ¼ 0.47)
* Within group comparison of BAþOT-LVR change scores (4-month follow-up person measure minus baseline person measure) for subjects with
VA of 20/70 or better (logMAR < 0.55); The P values are for 1-tailed paired t-tests comparing baseline person measures to 4-month follow-up person
measures.
† Results that reach statistical significance after correction for multiple tests. To get an alpha of 0.05, correction for multiple comparisons is
0.003 for the within group comparisons*–j j and 0.006 for each of the change score group comparisons.¶–††
‡ Within group comparison of BAþOT-LVR change scores (4-month follow-up person measure minus baseline person measure) for subjects with
VA worse than 20/70 (logMAR > 0.55). The values of P are for 1-tailed paired t-tests comparing baseline person measures to 4-month follow-up
person measures.
§ Within group comparison of ST change scores (4-month follow-up person measure minus baseline person measure) for subjects with VA of 20/
70 or better (logMAR < 0.55). The values of P are for 1-tailed paired t-tests comparing baseline person measures to 4-month follow-up person
measures.
jj Within group comparison of ST change scores (4-month follow-up person measure minus baseline person measure) for subjects with VA worse
than 20/70 (logMAR > 0.55). The values of P are for 1-tailed paired t-tests comparing baseline person measures to 4-month follow-up person
measures.
¶ Between group comparison of change scores (4-month follow-up person measure minus baseline person measure) for subjects with VA of 20/
70 or better (logMAR < 0.55); The values of P are for 1-tailed unpaired t-tests comparing BA þOT-LVR change scores to ST change scores.
# Between group comparison of change scores (4-month follow-up person measure minus baseline person measure) for subjects with VA worse
than 20/70 (logMAR > 0.55). The values of P are for 1-tailed unpaired t-tests comparing BA þOT-LVR change scores to ST change scores.
** Within group comparison of BAþOT-LVR change scores (4-month follow-up person measure minus baseline person measure); The values of P
are for 1-tailed paired t-tests comparing subjects with VA of 20/70 or better to subjects with VA worse than 20/70.
†† Within group comparison of ST change scores (4-month follow-up person measure minus baseline person measure). The values of P are for
1-tailed paired t-tests comparing subjects with VA of 20/70 or better to subjects with VA worse than 20/70.
FIGURE. Person measure PHQ-9 change scores in depression severity from baseline to 4-month follow-up by treatment group. Negative change
scores indicate decreases in depressed mood and positive change scores indicate increases in depression severity (highlighted area).
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that subjects with improvements in functional ability had a
greater decrease in depression severity after intervention than
those who did not improve in functional ability (P ¼ 0.036).
Similar results were observed at the task level with only
reading tasks exhibiting a statistically significant effect of
functional ability improvement on depression severity.
However, despite the significant effect at the goal level,
there is no correlation between changes in visual ability and
changes in depression severity (r ¼0.0725, P ¼ 0.183).
There was no difference between the two visual acuity
groups in depression severity at baseline (mean ¼ 1.37 for
acuity <20/70 and mean¼1.34 for acuity ‡20/70, P¼ 0.71).
However, after intervention, subjects with VA ‡20/70 had a
greater improvement in depression severity (mean change ¼
0.94) than did those with VA <20/70 (mean change¼0.34;
P ¼ 0.0048).
DISCUSSION
Improvements in low vision patients’ ability to perform daily
activities, as measured by the AI, were consistently greater for
the BAþOT-LVR group than for the ST group. These results lead
us to conclude that functional outcomes are better when
occupational therapy is added to standard optometric low
vision services than when an equivalent amount of attention
only is added. The significant improvements in visual ability we
saw in the ST group can be interpreted as concurring with
previous studies that concluded that conventional low vision
services alone are effective at improving visual function.12–19
However, those results also could be interpreted as indicative
of a response-biasing effect of supportive therapy.
The results of the current study attest specifically to the
efficacy of in-home low vision services by an occupational
therapist in patients with comorbid depressive symptoms. The
added effects of occupational therapy were greater for patients
with less severe visual impairments (‡20/70) than they were
for patients with more severe visual impairments (<20/70).
This result was unexpected because, as shown in the LOVIT
study,13 patients with better visual function at baseline have
less room to improve.
We observed that for both the BAþOT-LVR and ST treatment
groups, visual ability measures estimated for AI goal difficulty
ratings improved by similar large amounts even though the ST
group received no LVR beyond the initial optometric low vision
services. With the extensive personal attention given to both
groups by the therapists, we must consider the possibility that
there could be changes in response bias secondary to
improvements in mood resulting from attention alone, which
could then be responsible for most of the observed effects. This
hypothesis is strengthened by the observation of a greater
reduction in depression severity for patients in both groups who
had significant improvements in functional ability, based on
MCID, than for patients who did not have significant improve-
ments. In other words, the severity of depression, rather than or
in addition to an actual change in ability, may influence patient’s
judgments about the difficulty of performing activities, espe-
cially when rating the very broadly described AI goals.
Similar effects of MCID were seen when looking at the
reading level, meaning there were greater improvements in
depression severity for those with significant improvement in
reading ability compared to those without significant improve-
ment in reading ability. At the group level, significant
improvements in reading ability were seen for BA þ OT-LVR
patients with VA ‡20/70, but, there were no significant
improvements for BA þ OT-LVR subjects with VA <20/70.
These results suggest that after the initial services provided by
the optometrist, there was no additional benefit from in-home
OT-LVR for those subjects with poorer vision.
The study design selected for a specific demographic of
patients who were considered ‘‘at-risk’’ for developing
clinically significant depression. The groups BA þOT-LVR and
ST exhibited equal reductions in depression severity after
intervention (see Fig.). Although the magnitude of improve-
ment in functional ability did not correlate with the magnitude
of reduction in depression severity, the magnitude of reduction
in depression severity was significantly greater for patients
who had a minimum clinically important difference (MCID of
1) in functional ability at the goal level after intervention.
However, we cannot draw conclusions about cause and effect
from these observations—elevations of mood from the
personal attention both groups received from repeated visits
by an OT or social worker/counselor over an 8-week period
could cause changes in response bias (i.e., making all activities
seem easier), or improvements in functional ability from the
optometric low vision services provided to both groups before
additional in-home psychotherapy could cause elevations in
mood (e.g., secondary to reductions in stress). Alternatively, it
can be hypothesized that improved visual function contributed
to the decline in depression severity. The VITAL study was not
designed to test these alternative hypotheses.
Because both groups received optometric care by a low
vision optometrist before randomization, which included initial
device evaluation and training, any functional impact from the
optometric care given before the home visits would be
expected to contribute to both groups’ treatment effects.
Based on the overall treatment effects seen in the attention
control ST group when measured at the task level, it appears
that the optometric services and provision of visual assistive
equipment without additional OT services only significantly
improved functional ability in inside-the-home tasks.
The most likely scenario is that both effects are occurring:
the optometric services plus low vision devices may be
responsible for improvements in ability and the attention from
the therapists may bias the patients’ use of the rating scale.
When compared to the broad goal level assessments, task
descriptions are much more specific with possibly less room
for interpretation and response bias.
Because the subjects in the VITAL study were selected to
represent low vision patients at high risk for developing severe
depression, the effect of depression severity on measures of
functional ability may be particularly strong. Besides improve-
ments for both groups in functional ability estimated from
TABLE 3. Change Scores of PHQ-9 Mean Depression Severity
MCID Outcome Goal Reading Inside-the-Home Outside-the-Home
Mean DPHQ-9 MCID 01 0.87 0.52 0.56 0.52
Mean DPHQ-9 MCID 12 1.26 0.94 0.80 0.85
One-tailed t-test P ¼ 0.036 P ¼ 0.044 P ¼ 0.18 P ¼ 0.12
For subjects with binary MCID scores of 0 (no significant improvement in functional ability)1 and 1 (significant improvement in functional
ability)2 based on visual ability person measures estimated from AI goal responses and the 3 different sets of AI task responses (reading, inside-the-
home, and outside-the-home tasks).
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difficulty ratings of daily activities, both groups also showed
significant improvements in depression severity estimated from
PHQ-9 scores. Recent studies showed that depressed mood,
estimated from Rasch analysis of responses to the geriatric
depression scale, was a strong predictor in low vision patients
of baseline functional ability measured with the AI,32 but was
not associated with changes in functional ability measured after
low vision rehabilitation.15 Given these corroborating observa-
tions, the results of the present study have to make us
concerned about possible confounding effects of depression
severity on the measurement per se of functional ability.
The limitation of the analysis presented here is that the
VITAL study was not designed to distinguish the separate
contributions to functional ability outcome measures of
optometric low vision services, low vision rehabilitation
services (plus BA) provided in the patient’s home, and the
confounding effects of depression severity. A study specifically
designed to determine the independent effects of each of these
factors on the functional outcomes of low vision rehabilitation
is required to properly evaluate the effectiveness of low vision
rehabilitation services.
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